Literature DB >> 3987701

Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients.

M E Girelli, B Busnardo, R Amerio, G Scotton, D Casara, C Betterle, M Piccolo, M R Pelizzo.   

Abstract

UNLABELLED: Serum thyroglobulin (Tg) was measured in 429 patients with well-differentiated thyroid carcinoma, during thyroid hormone suppression therapy. 324 patients out of 429 were considered free of disease; 44 had only remnants in the thyroid bed; 61 had metastases, of them 40 were detected by TBS and 21 were nonfunctioning and were detected by other diagnostic procedures. Tg was measured by a RIA method in 257 patients and by an IRMA method in 277 patients. The correlation between the two methods was very good (r = 0.914) for values higher than 25 ng/ml with the RIA method. The cut-off limit to distinguish pathological from nonpathological values was considered the mean value found in the patients free of disease plus 2SD. The cut-off limit for the RIA method was 24.2 ng/ml and 3.0 ng/ml for the IRMA method. Of patients with high Tg levels 92% had metastases, either nodal or distant; only 8% had remnants in the thyroid bed. Tg levels were high in 80% of the patients with metastases, all but two of the patients with metastases and low Tg levels had nodal metastases. Moreover, Tg levels were high in 76% of the patients with metastases unable to take up radioiodine. IN
CONCLUSION: patients with low levels of serum Tg during suppression therapy have a high probability of being free of disease, even though the presence of tumors cannot be excluded. On the other hand a value greater than the cut-off limit suggests the presence of metastases despite a negative scan.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987701     DOI: 10.1007/bf00254469

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  13 in total

1.  Serum thyroglobulin levels in healthy subjects and in patients with thyroid disease.

Authors:  G Torrigiani; D Doniach; I M Roitt
Journal:  J Clin Endocrinol Metab       Date:  1969-03       Impact factor: 5.958

2.  Serum thyroglobulin levels predict total body iodine scan findings in patients with treated well-differentiated thyroid carcinoma.

Authors:  M A Charles; L E Dodson; N Waldeck; F Hofeldt; N Ghaed; R Telepak; J Ownbey; P Burstein
Journal:  Am J Med       Date:  1980-09       Impact factor: 4.965

3.  Serum thyroglobulin levels in patients with differentiated thyroid carcinoma.

Authors:  A J Van Herle
Journal:  Ann Radiol (Paris)       Date:  1977 Nov-Dec

4.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.

Authors:  A J Herle; R P Uller
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

5.  TSH levels and TSH response to TRH as a guide to the replacement treatment of patients with thyroid carcinoma.

Authors:  B Busnardo; R Vagelista; M E Girelli; F Bui; C Lazzi
Journal:  J Clin Endocrinol Metab       Date:  1976-05       Impact factor: 5.958

6.  Serum thyroglobulin differentiated thyroid carcinoma: histological and metastatic classification.

Authors:  D H Shah; S R Dandekar; R K Jeevanram; A Kumar; S M Sharma; R D Ganatra
Journal:  Acta Endocrinol (Copenh)       Date:  1981-10

7.  Serum thyroglobulin in the diagnosis and management of thyroid carcinoma.

Authors:  A H Shlossberg; J C Jacobson; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1979-01       Impact factor: 3.478

8.  Serum thyroglobulin and recurrent thyroid cancer.

Authors:  P L Gerfo; T Stillman; D Colacchio; C Feind
Journal:  Lancet       Date:  1977-04-23       Impact factor: 79.321

9.  [Serum thyroglobulin estimation for follow-up of patients with thyroid carcinoma (author's transl)].

Authors:  H Botsch; E Schulz; B Lochner
Journal:  Dtsch Med Wochenschr       Date:  1979-07-27       Impact factor: 0.628

10.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

Authors:  M W Ashcraft; A J Van Herle
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

View more
  5 in total

1.  Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer.

Authors:  D Rubello; M E Girelli; D Casara; M Piccolo; A Perin; B Busnardo
Journal:  J Endocrinol Invest       Date:  1990-10       Impact factor: 4.256

2.  Critical evaluation of serum thyroglobulin (Tg) levels during thyroid hormone suppression therapy versus Tg levels after hormone withdrawal and total body scan: results in 291 patients with thyroid cancer.

Authors:  M E Girelli; B Busnardo; R Amerio; D Casara; C Betterle; M Piccolo
Journal:  Eur J Nucl Med       Date:  1986

3.  The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy.

Authors:  J L Pasieka; N W Thompson; M K McLeod; R E Burney; M Macha
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

4.  Serum thyroglobulin as a preclinical tumour marker in subgroups of thyroid cancer.

Authors:  S O Thoresen; O Myking; E Glattre; K Rootwelt; A Andersen; O P Foss
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

5.  Multicentricity in the thyroid differentiated carcinoma.

Authors:  José Francisco Salles Chagas; José Luís Braga de Aquino; Maria Beatriz Nogueira Pascoal; Adriana Soave Teixeira; Márcia Maria Nunes Ferro; Mariana Cristina Ortiz Gambaro; Rogério Aparecido Dedivitis
Journal:  Braz J Otorhinolaryngol       Date:  2009 Jan-Feb
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.